We are upgrading the repository! The content freeze has been extended to December 11, 2024, when we expect the new repository to become available. New submissions or changes to existing items will not be allowed until after the new website goes live. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.
Is this the end for ranitidine? NDMA presence continues to confound
UMass Chan Affiliations
UMass Memorial Children's Medical CenterDepartment of Pediatrics, Division of Pediatric Gastroentrology
Document Type
Journal ArticlePublication Date
2021-07-01Keywords
N-nitrosodimethylamineNDMA
ranitidine
Health Policy
Pharmacy Administration, Policy and Regulation
Metadata
Show full item recordAbstract
N-nitrosodimethylamine (NDMA), a probable human carcinogen, was discovered decades ago, although elevated levels in several widely used drugs were detected only recently. Several medications that are now known to contain NDMA have remained available, whereas ranitidine has been completely withdrawn from the market. In the following paper, we discuss the overview of events that led to the withdrawal of ranitidine and compare evidence and subsequent regulatory response of other medications also containing NDMA.Source
Wagner JA, Dinh JC, Lightdale JR, Gold BD, Colombo JM. Is this the end for ranitidine? NDMA presence continues to confound. Clin Transl Sci. 2021 Jul;14(4):1197-1200. doi: 10.1111/cts.12995. Epub 2021 May 2. PMID: 33934515; PMCID: PMC8301580. Link to article on publisher's site
DOI
10.1111/cts.12995Permanent Link to this Item
http://hdl.handle.net/20.500.14038/41915PubMed ID
33934515Related Resources
Rights
Copyright © 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.Distribution License
http://creativecommons.org/licenses/by-nc/4.0/Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2021 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.